Details of the Drug

General Information of Drug (ID: DMR8ONJ)

Drug Name
Leflunomide
Synonyms
Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
Indication
Disease Entry ICD 11 Status REF
Arthritis FA20 Approved [1]
Lupus nephritis 4A40.0Y Approved [2]
Multiple sclerosis 8A40 Approved [3]
Psoriatic arthritis FA21 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [4]
Therapeutic Class
Antiinflammatory Agents
Affected Organisms
Humans and other mammals
ATC Code
L04AA13: Leflunomide
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 270.21
Logarithm of the Partition Coefficient (xlogp) 2.5
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [6]
Elimination
1% of drug is excreted from urine in the unchanged form [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.23236 micromolar/kg/day [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.023 mg/mL [5]
Chemical Identifiers
Formula
C12H9F3N2O2
IUPAC Name
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
Canonical SMILES
CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
InChI
InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
InChIKey
VHOGYURTWQBHIL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3899
ChEBI ID
CHEBI:6402
CAS Number
75706-12-6
UNII
G162GK9U4W
DrugBank ID
DB01097
TTD ID
D08ROP
VARIDT ID
DR00130
INTEDE ID
DR0921
ACDINA ID
D00352
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) TT3PQ2Y PYRD_PLAF7 Inhibitor [8]
HUMAN dihydroorotate dehydrogenase (DHODH) TT3UY29 PYRD_HUMAN Inhibitor [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Gene/Protein Processing [14]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5) OTNY3VMD PLCE_HUMAN Gene/Protein Processing [14]
10 kDa heat shock protein, mitochondrial (HSPE1) OT7JSZLB CH10_HUMAN Gene/Protein Processing [14]
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2) OT3K7HY5 DHB2_HUMAN Gene/Protein Processing [14]
182 kDa tankyrase-1-binding protein (TNKS1BP1) OTBIZECQ TB182_HUMAN Gene/Protein Processing [14]
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP) OTB8HCED CN37_HUMAN Gene/Protein Processing [14]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Gene/Protein Processing [14]
26S proteasome non-ATPase regulatory subunit 12 (PSMD12) OTWICA51 PSD12_HUMAN Gene/Protein Processing [14]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Gene/Protein Processing [14]
3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 (FUT3) OTXQ6P8R FUT3_HUMAN Gene/Protein Processing [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 158 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JM1 GDSC2 5.5409 9.4218 4.2549 18.5536
MOLM-13 GDSC2 0.0169 16.7734 -4.6282 55.1888
JVM-3 GDSC2 1.7438 15.7738 -2.4496 49.6927
VAL GDSC2 3.3739 11.8436 0.9895 40.3261
SUP-B8 GDSC2 3.382 6.1786 3.1995 33.6154
RPMI-8866 GDSC2 3.6458 14.7702 -0.1257 41.0133
RC-K8 GDSC2 3.6699 7.4872 3.1343 32.4284
BL-41 GDSC2 3.7893 8.3866 2.9255 32.7341
BALL-1 GDSC2 3.8253 10.0123 2.2736 34.98
Jiyoye GDSC2 3.9638 10.9238 2.0012 35.2062
SU-DHL-5 GDSC2 4.0265 5.3555 4.0107 26.3455
SR GDSC2 4.0344 7.4638 3.5365 28.7425
H9 GDSC2 4.0649 9.4196 2.7802 32.0131
CML-T1 GDSC2 4.1547 6.8492 3.8686 26.4701
RCH-ACV GDSC2 4.2056 6.6199 3.9894 25.5949
SU-DHL-10 GDSC2 4.2098 8.3782 3.373 28.7274
Namalwa GDSC2 4.228 10.3845 2.5127 32.3084
DB GDSC2 4.3301 8.3666 3.5042 27.5406
A3/Kawakami GDSC2 4.5674 9.2865 3.3525 27.2437
SU-DHL-1 GDSC2 4.5816 8.2177 3.8297 24.753
Jurkat GDSC2 4.5874 29.647 -6.6134 43.719
Raji GDSC2 4.5943 7.0269 4.292 22.1789
697 GDSC2 4.679 10.4033 2.9515 28.6111
SUP-M2 GDSC2 4.6996 9.8105 3.2473 27.1865
MOLT-16 GDSC2 4.71 9.5313 3.3858 26.4789
GA-10 GDSC2 4.7592 8.3491 3.9599 23.2928
BV-173 GDSC2 4.7897 7.883 4.1857 21.9155
SU-DHL-16 GDSC2 4.8194 7.9679 4.1823 21.8085
NB4 GDSC2 4.8244 9.3865 3.5667 25.1022
SU-DHL-8 GDSC2 4.8576 14.2272 1.2771 33.6905
NALM-6 GDSC2 4.8701 8.5222 3.9999 22.6109
DoHH2 GDSC2 4.8926 6.5069 4.7682 18.2244
SU-DHL-6 GDSC2 4.9198 6.991 4.6572 18.7087
JeKo-1 GDSC2 4.928 6.8774 4.7027 18.4198
P12-Ichikawa GDSC2 4.9695 11.1177 2.8942 27.6886
AMO1 GDSC2 4.9775 8.7777 3.9967 22.1892
NU-DUL-1 GDSC2 4.984 7.1355 4.6778 18.311
DEL GDSC2 4.9928 10.2506 3.3303 25.5978
Karpas-1106P GDSC2 5.0406 9.803 3.5881 24.121
JURL-MK1 GDSC2 5.0713 8.6666 4.1416 21.0026
Daudi GDSC2 5.0763 11.17 2.9709 26.9374
MV4-11 GDSC2 5.0842 11.6575 2.7426 27.8874
BC-1 GDSC2 5.1069 9.8004 3.6542 23.5178
SK-MM-2 GDSC2 5.1149 9.9337 3.5992 23.772
LAMA-84 GDSC2 5.1157 7.818 4.5552 18.4525
ARH-77 GDSC2 5.1433 11.0105 3.1115 26.0445
P32/ISH GDSC2 5.151 9.9107 3.6451 23.3933
MN-60 GDSC2 5.1746 12.4496 2.441 28.754
VL51 GDSC2 5.2782 7.7822 4.7402 16.7136
TALL-1 [Human adult T-ALL] GDSC2 5.3088 9.3433 4.067 20.4955
KY821 GDSC2 5.3211 8.5615 4.4415 18.2941
L-540 GDSC2 5.3282 9.2136 4.1469 19.969
RL GDSC2 5.3333 8.5082 4.478 18.0326
U-698-M GDSC2 5.3362 12.3073 2.6601 27.2868
EM-2 GDSC2 5.3388 11.1456 3.2305 24.7486
CTB-1 GDSC2 5.385 9.0447 4.2819 18.9783
BE-13 GDSC2 5.388 13.1094 2.3129 28.4647
HC-1 GDSC2 5.4094 9.9021 3.8987 21.0523
Ku812 GDSC2 5.4353 10.3083 3.7277 21.881
CA46 GDSC2 5.45 11.6525 3.0862 25.015
HEL GDSC2 5.4815 9.0983 4.3512 18.2122
CTV-1 GDSC2 5.4859 8.674 4.5543 16.9989
SIG-M5 GDSC2 5.4959 7.9574 4.8897 14.9635
KMS-12-BM GDSC2 5.4963 7.9349 4.9001 14.9005
GDM-1 GDSC2 5.6267 10.9891 3.5746 21.9893
A4/Fukuda GDSC2 5.6342 11.9838 3.0919 24.3282
ML-2 GDSC2 5.6401 8.1243 4.9612 13.979
DG-75 GDSC2 5.6489 12.8933 2.6556 26.1919
SU-DHL-4 GDSC2 5.6506 7.8164 5.1102 13.045
MC116 GDSC2 5.6585 8.7703 4.6787 15.6131
GR-ST GDSC2 5.666 8.6197 4.757 15.1138
SUP-T1 GDSC2 5.6788 8.4921 4.8295 14.6287
Hs 445 GDSC2 5.7022 10.6944 3.7887 20.5893
ALL-PO GDSC2 5.7069 16.0873 1.1202 31.2547
DND-41 GDSC2 5.7153 8.617 4.8065 14.6338
PL-21 GDSC2 5.7643 9.61 4.3763 17.0391
TUR GDSC2 5.7823 9.4785 4.4572 16.4963
PF-382 GDSC2 5.7974 11.1936 3.6301 21.1001
Karpas-422 GDSC2 5.8075 8.4174 4.9906 13.1777
Ramos.2G6.4C10 GDSC2 5.8099 10.1963 4.1324 18.2987
MY-M12 GDSC2 5.8312 9.9604 4.2677 17.4425
ST486 GDSC2 5.8394 8.513 4.9764 13.1488
BONNA-12 GDSC2 5.8481 10.5588 3.9892 18.977
CCRF-CEM GDSC2 5.8705 8.0399 5.2296 11.4887
L-1236 GDSC2 5.9185 9.0175 4.8091 13.8928
KOPN-8 GDSC2 5.9217 11.1539 3.7619 19.9731
JVM-2 GDSC2 5.9258 8.5647 5.0347 12.4821
KE-37 GDSC2 5.9284 9.8696 4.4018 16.3189
OCI-AML-3 GDSC2 5.9364 12.3641 3.1747 22.8977
HAL-01 GDSC2 5.9423 8.9372 4.8705 13.4339
MOLT-13 GDSC2 5.9472 9.5283 4.5866 15.1475
NK-92MI GDSC2 5.949 8.4557 5.1093 11.9412
MLMA GDSC2 5.9689 9.7988 4.4737 15.7526
NCI-H929 GDSC2 5.9743 7.9781 5.3607 10.3059
Loucy GDSC2 5.9834 7.677 5.5096 9.3645
Karpas-620 GDSC2 6.0012 12.6192 3.1051 23.0085
KMS-11 GDSC2 6.0294 12.1962 3.3403 21.785
SUP-HD1 GDSC2 6.0682 9.2187 4.85 13.1295
Karpas-231 GDSC2 6.0831 12.2916 3.3401 21.6081
Granta-519 GDSC2 6.1213 11.9486 3.5443 20.4524
MOLM-16 GDSC2 6.1218 9.6466 4.6879 13.9455
RPMI-6666 GDSC2 6.1222 14.3968 2.3245 25.9435
TK [Human B-cell lymphoma] GDSC2 6.1242 10.0591 4.486 15.1607
ATN-1 GDSC2 6.1245 8.7147 5.1491 11.0864
OCI-AML-5 GDSC2 6.158 13.6094 2.7484 24.0953
MHH-PREB-1 GDSC2 6.1787 9.3053 4.908 12.4039
LP-1 GDSC2 6.1823 8.3284 5.3917 9.3799
Farage GDSC2 6.2099 9.7571 4.7123 13.5087
OCI-AML-2 GDSC2 6.2129 8.1891 5.4881 8.6751
EB2 GDSC2 6.2217 9.5518 4.8246 12.7798
SKM-1 GDSC2 6.2354 8.6035 5.3058 9.7377
L-428 GDSC2 6.2377 10.7369 4.2497 16.1902
IM-9 GDSC2 6.2396 8.5289 5.3463 9.4702
MEG-01 GDSC2 6.2468 9.0322 5.1045 10.9591
MOLT-4 GDSC2 6.2607 7.6669 5.7861 6.658
OCI-Ly7 GDSC2 6.3007 8.9776 5.1799 10.3127
BC-3 GDSC2 6.3171 8.9043 5.2309 9.9402
SCC-3 GDSC2 6.3238 8.4526 5.4606 8.4772
KCL-22 GDSC2 6.3288 11.3105 4.043 17.0865
P30/OHK GDSC2 6.3288 9.0659 5.1612 10.3397
CESS GDSC2 6.35 9.291 5.0681 10.8554
RS4;11 GDSC2 6.359 9.0775 5.1822 10.1124
RPMI-8226 GDSC2 6.3599 9.0136 5.2147 9.9056
CRO-AP2 GDSC2 6.3672 9.0043 5.2259 9.8122
WSU-NHL GDSC2 6.3867 7.7153 5.8812 5.6321
OCI-M1 GDSC2 6.3974 9.1707 5.1696 10.0709
JSC-1 GDSC2 6.407 12.8261 3.3532 20.5025
K-562 GDSC2 6.4096 9.3807 5.0756 10.6218
ALL-SIL GDSC2 6.4275 10.5709 4.4972 14.1263
EoL-1 GDSC2 6.4337 7.8944 5.8358 5.7616
MHH-CALL-2 GDSC2 6.4502 9.2881 5.1571 9.9855
Reh GDSC2 6.4586 9.449 5.0841 10.4175
LC4-1 GDSC2 6.5279 9.2247 5.2556 9.1289
Kasumi-1 GDSC2 6.574 11.246 4.2843 14.9418
OPM-2 GDSC2 6.5835 8.7612 5.5344 7.2014
MM1.S GDSC2 6.6198 9.2039 5.3437 8.2995
HH [Human lymphoma] GDSC2 6.6465 9.5842 5.1759 9.279
ME1 GDSC2 6.6475 8.8242 5.5567 6.8723
Karpas-45 GDSC2 6.6505 10.9039 4.5193 13.3197
L-363 GDSC2 6.6573 18.2375 0.8582 29.1743
MHH-CALL-4 GDSC2 6.6613 13.1366 3.412 19.4289
HL-60 GDSC2 6.694 11.7332 4.1408 15.4126
U266B1 GDSC2 6.704 9.3072 5.3619 7.9408
NOMO-1 GDSC2 6.7154 9.0362 5.5068 6.9931
HT GDSC2 6.737 10.0908 4.9974 10.1356
MOLP-8 GDSC2 6.742 10.9466 4.5737 12.725
QIMR-WIL GDSC2 6.7642 9.9451 5.0924 9.4646
WIL2 NS GDSC2 6.7777 11.7998 4.1766 14.9617
ROS-50 GDSC2 6.7854 12.0108 4.0774 15.5046
KG-1 GDSC2 6.7881 8.403 5.8814 4.4239
OCI-Ly19 GDSC2 6.8608 10.9404 4.6736 11.7811
KMOE-2 GDSC2 6.8849 9.4974 5.4126 7.1201
THP-1 GDSC2 6.9043 12.3477 4.006 15.5622
HDLM-2 GDSC2 6.985 9.6079 5.4357 6.7113
SUP-B15 GDSC2 7.0155 9.1653 5.6779 5.1167
EJM GDSC2 7.029 8.7399 5.8969 3.7204
KM-H2 GDSC2 7.1584 9.9682 5.3886 6.5673
JJN-3 GDSC2 8.0042 14.7398 3.666 14.4931
⏷ Show the Full List of 158 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ESO-51 GDSC2 4.5552 14.9307 0.6528 36.2869
ESO-26 GDSC2 6.7959 14.8012 2.6912 22.3804
OACM5.1 C GDSC2 6.8286 12.6678 3.7844 16.9955
OACP4 C GDSC2 7.0215 9.3623 5.5851 5.6817
KYSE-220 GDSC2 7.024 11.2795 4.6347 11.5653
TE-12 GDSC2 7.0668 10.5836 5.0144 9.1263
KYAE-1 GDSC2 7.2194 11.9405 4.4586 12.0916
KYSE-50 GDSC2 7.3293 10.1522 5.4229 5.9475
HCE-4 GDSC2 7.4644 13.9265 3.6617 15.882
FLO-1 GDSC2 7.5457 11.6899 4.8273 9.0707
SK-GT-4 GDSC2 9.3246 19.8075 2.1403 18.3336
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 5.4717 9.5877 4.109 19.6461
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-5 GDSC2 2.661 13.4162 -0.4458 45.3066
KP-N-YS GDSC2 3.2281 9.7167 1.787 39.3201
SJNB-6 GDSC2 4.8699 8.3146 4.0894 22.1159
SK-N-MC-IXC GDSC2 5.4395 12.947 2.4398 27.7961
GOTO GDSC2 5.7678 16.199 1.1179 31.0693
KP-N-YN GDSC2 5.8836 11.0176 3.7951 19.9243
SJNB-7 GDSC2 5.8935 9.4669 4.5668 15.4517
Kelly GDSC2 5.9019 9.6158 4.5019 15.8129
SJNB-14 GDSC2 5.9434 8.5886 5.04 12.3877
CHP-134 GDSC2 6.0745 9.8098 4.5646 14.8518
KP-N-RT-BM-1 GDSC2 6.3107 8.8348 5.2597 9.7807
SJNB-13 GDSC2 6.5644 8.8392 5.4793 7.6073
NH-12 GDSC2 6.643 12.7395 3.5953 18.547
NB(TU)1 GDSC2 6.6641 8.5455 5.7099 5.8547
TGW GDSC2 6.6966 14.2974 2.8609 21.9316
NB69 GDSC2 6.7032 9.602 5.2139 8.8758
CHP-212 GDSC2 6.7125 14.5691 2.7383 22.4234
LA-N-6 GDSC2 6.8114 10.3579 4.9245 10.3781
SiMa GDSC2 6.8846 10.4461 4.9395 10.0817
SK-N-DZ GDSC2 6.9229 12.3085 4.0406 15.3154
MHH-NB-11 GDSC2 6.9232 10.6354 4.8758 10.3689
SJNB-17 GDSC2 6.9324 8.8884 5.752 4.8614
SJNB-10 GDSC2 7.0252 9.9113 5.316 7.3568
GI-ME-N GDSC2 7.0484 13.089 3.7519 16.54
SK-N-BE(2)-M17 GDSC2 7.0807 9.9429 5.3428 7.0472
SJNB-5 GDSC2 7.2945 10.5836 5.1864 7.4872
CHP-126 GDSC2 7.5082 11.0576 5.1092 7.4534
SK-N-AS GDSC2 7.9231 21.563 0.2217 27.6613
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 6.3897 8.8844 5.3053 9.2418
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EW-18 GDSC2 5.5038 11.0553 3.4285 23.1748
EW-16 GDSC2 5.7271 13.0408 2.6526 25.9343
EW-11 GDSC2 5.8879 11.7812 3.4209 21.8608
EW-13 GDSC2 5.9432 15.4002 1.6689 28.8487
SK-PN-DW GDSC2 6.0769 11.1167 3.919 18.5954
CADO-ES1 GDSC2 6.0825 13.5013 2.7368 24.3899
CAL-72 GDSC2 6.2606 17.3645 0.961 30.016
ES8 GDSC2 6.2616 12.1888 3.5467 19.9847
EW-1 GDSC2 6.3157 11.5091 3.9327 17.7455
HOS GDSC2 6.4914 11.9231 3.8761 17.5081
ES4 GDSC2 6.5062 14.7661 2.4675 24.1794
A-673 GDSC2 6.5143 11.1337 4.2901 15.0883
CHSA8926 GDSC2 6.5399 8.4038 5.6758 6.438
EW-7 GDSC2 6.6008 9.5496 5.1549 9.5447
EW-12 GDSC2 6.6124 9.7119 5.0836 9.958
EW-3 GDSC2 6.6819 13.4378 3.2785 20.0272
EW-24 GDSC2 6.6879 8.452 5.7762 5.3669
SK-ES-1 GDSC2 6.7438 10.9371 4.5799 12.6824
G-292 clone A141B1 GDSC2 6.8045 8.7186 5.7372 5.2903
TC-71 GDSC2 6.8139 14.1954 3.0089 20.9139
CHSA0108 GDSC2 6.8305 12.0076 4.1159 15.1557
EW-22 GDSC2 6.8428 10.9876 4.6355 12.063
ES7 GDSC2 6.9318 9.9997 5.1995 8.3326
NOS-1 [Human HNSCC] GDSC2 6.9821 13.0825 3.7019 16.9936
ES6 GDSC2 7.0572 11.6307 4.4859 12.3655
NY GDSC2 7.0723 11.0504 4.7866 10.5128
MHH-ES-1 GDSC2 7.1793 12.6375 4.0807 14.3757
ES5 GDSC2 7.3117 10.7129 5.1355 7.7589
H-EMC-SS GDSC2 7.3624 11.7544 4.6599 10.5257
U2OS GDSC2 7.5923 12.2952 4.5644 10.5214
CHSA0011 GDSC2 7.6696 10.143 5.6574 3.8168
CAL-78 GDSC2 7.6831 11.8584 4.8437 8.6497
U-CH2 GDSC2 7.6991 14.0387 3.7848 14.628
MG-63 GDSC2 7.7051 15.9971 2.8195 19.3125
SaOS-2 GDSC2 7.8208 13.7196 4.0325 12.9895
HuO-3N1 GDSC2 8.104 10.3407 5.8237 2.1829
HuO9 GDSC2 8.4609 18.7246 2.0428 20.6364
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-468 GDSC2 5.6008 14.8782 1.6281 30.0911
HCC1599 GDSC2 5.7493 10.6446 3.8565 20.0555
MDA-MB-453 GDSC2 5.8666 16.4137 1.097 30.8199
HCC1187 GDSC2 6.1298 10.6554 4.1951 16.8571
MDA-MB-157 GDSC2 6.1382 9.5629 4.7441 13.5477
DU4475 GDSC2 6.2353 10.4946 4.3682 15.5013
MDA-MB-330 GDSC2 6.3215 9.7283 4.8254 12.4554
MDA-MB-415 GDSC2 6.3256 10.6396 4.3749 15.1743
HDQ-P1 GDSC2 6.3274 8.6888 5.347 9.1789
EFM-192A GDSC2 6.4099 11.5929 3.9718 17.2311
HCC2157 GDSC2 6.4108 8.2313 5.6484 7.0147
CAMA-1 GDSC2 6.4979 12.0151 3.8357 17.709
HCC1954 GDSC2 6.5359 8.0586 5.8446 5.3835
BT-20 GDSC2 6.5382 8.0787 5.8366 5.4269
CAL-85-1 GDSC2 6.5742 17.7933 1.011 28.9743
MRK-nu-1 GDSC2 6.6073 8.6284 5.6209 6.5835
CAL-51 GDSC2 6.6333 15.1388 2.3876 24.1181
MCF-7 GDSC2 6.7076 8.9323 5.5523 6.7279
CAL-120 GDSC2 6.7295 13.3447 3.3645 19.4616
HCC1806 GDSC2 6.7384 10.3615 4.8632 10.9649
MDA-MB-231 GDSC2 6.7621 10.4719 4.8275 11.1181
MFM-223 GDSC2 6.784 11.1189 4.522 12.915
AU565 GDSC2 6.7972 9.7074 5.2379 8.4593
HCC1419 GDSC2 6.877 9.0082 5.65 5.6464
HCC1937 GDSC2 6.8771 10.2335 5.0395 9.4804
COLO 824 GDSC2 6.9325 9.7873 5.3057 7.6647
JIMT-1 GDSC2 6.9918 9.7997 5.3457 7.2577
BT-474 GDSC2 7.037 12.859 3.8575 16.0032
HCC1569 GDSC2 7.0497 11.3918 4.5991 11.7096
Evsa-T GDSC2 7.0615 10.246 5.1779 8.1249
Hs 578T GDSC2 7.0785 15.7144 2.4656 22.515
OCUB-M GDSC2 7.1111 10.3632 5.1578 8.1218
HCC2218 GDSC2 7.1383 10.1732 5.2724 7.3407
EFM-19 GDSC2 7.1703 11.2826 4.7473 10.4934
UACC-893 GDSC2 7.218 12.3976 4.2303 13.4223
HCC1500 GDSC2 7.2189 11.3856 4.7335 10.4502
HCC1143 GDSC2 7.5099 16.7262 2.305 21.9869
HCC70 GDSC2 7.5167 12.7825 4.2681 12.4271
MDA-MB-361 GDSC2 7.5275 12.2354 4.5459 10.7888
YMB-1-E GDSC2 7.6573 12.0616 4.7261 9.4098
BT-549 GDSC2 7.832 15.8284 3.0003 18.1713
HCC38 GDSC2 7.8405 10.4433 5.6247 3.6902
MDA-MB-436 GDSC2 8.0513 17.5059 2.3366 20.4755
ZR-75-30 GDSC2 8.0746 16.5235 2.8398 18.2891
T-47D GDSC2 8.1146 10.4427 5.7848 2.3688
HCC1428 GDSC2 8.2457 13.0037 4.6795 8.3751
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-172 GDSC2 5.2537 10.922 3.2589 24.9317
PFSK-1 GDSC2 5.2882 9.5643 3.9426 21.2672
D-336MG GDSC2 6.0493 10.3374 4.2809 16.6243
D-423MG GDSC2 6.0952 8.7681 5.0958 11.517
GB-1 GDSC2 6.2141 8.7879 5.1955 10.4977
AM-38 GDSC2 6.3552 10.7436 4.3487 15.2365
8-MG-BA GDSC2 6.4122 11.1707 4.1846 16.016
D-392MG GDSC2 6.5928 12.606 3.6202 18.5691
LN-405 GDSC2 6.6274 9.7888 5.0576 10.0767
YH-13 GDSC2 6.6332 12.6138 3.65 18.2907
Hs 683 GDSC2 6.7577 9.3612 5.3788 7.6823
CAS-1 GDSC2 6.7776 9.9703 5.0908 9.4372
Onda 10 GDSC2 6.7828 9.9362 5.112 9.2898
T98G GDSC2 6.8388 9.3672 5.441 7.066
ONS-76 GDSC2 6.8513 10.237 5.0171 9.6912
SF295 GDSC2 6.8625 11.4631 4.4139 13.334
SF126 GDSC2 6.8731 8.213 6.0412 3.1985
LN-18 GDSC2 6.8894 9.6163 5.357 7.4583
U-118MG GDSC2 6.9104 10.6173 4.8747 10.4109
D-247MG GDSC2 6.9634 11.5231 4.4651 12.7471
SF539 GDSC2 6.968 17.145 1.6609 25.8338
SW1088 GDSC2 6.9872 10.1323 5.1769 8.326
D-566MG GDSC2 7.0647 8.8166 5.8851 3.7096
KINGS-1 GDSC2 7.0799 16.5947 2.027 24.2215
DK-MG GDSC2 7.0832 9.4503 5.5878 5.5119
D283 Med GDSC2 7.1043 15.7023 2.4924 22.3322
SF268 GDSC2 7.1537 11.6571 4.5484 11.7335
D-502MG GDSC2 7.1681 9.3508 5.6985 4.6224
U-87MG ATCC GDSC2 7.2321 10.5332 5.165 7.7721
M059J GDSC2 7.2431 16.2605 2.3253 22.6244
KNS-81-FD GDSC2 7.253 11.8528 4.528 11.5928
SK-MG-1 GDSC2 7.2855 12.8807 4.0427 14.3019
NMC-G1 GDSC2 7.3013 13.8613 3.5673 16.808
KS-1 [Human Krukenberg tumour] GDSC2 7.3149 11.2489 4.8738 9.3534
SNB-75 GDSC2 7.4469 11.1337 5.0279 8.0924
D-263MG GDSC2 7.4931 12.4174 4.4306 11.5496
D-542MG GDSC2 7.5412 14.4295 3.4712 16.6564
GaMG GDSC2 7.5792 12.8155 4.2986 12.0956
LN-229 GDSC2 7.6558 16.1079 2.7264 19.8496
GI-1 GDSC2 7.6742 12.4266 4.5597 10.3508
KNS-42 GDSC2 7.7275 13.0168 4.3092 11.6697
Onda 11 GDSC2 7.7829 14.9608 3.3923 16.4268
D-245MG GDSC2 7.8129 12.2695 4.7357 8.9923
U-251MG GDSC2 7.9587 12.0211 4.9564 7.3705
DBTRG-05MG GDSC2 8.0615 14.929 3.6152 14.6159
42-MG-BA GDSC2 8.0928 14.7395 3.7309 13.9442
KALS-1 GDSC2 8.1037 16.4237 2.9109 17.8999
H4 GDSC2 8.1759 18.2256 2.075 21.1943
Daoy GDSC2 8.177 15.9918 3.1779 16.4888
Becker GDSC2 8.5457 14.6044 4.1153 10.8798
YKG-1 GDSC2 8.6319 16.7065 3.1577 15.5206
⏷ Show the Full List of 51 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 6.6618 9.2721 5.3446 8.1715
ETK-1 GDSC2 7.5541 10.8098 5.2621 6.4202
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MFE-280 GDSC2 5.8024 11.6039 3.4318 22.0995
AN3-CA GDSC2 5.8346 11.1559 3.6824 20.696
EN GDSC2 6.0408 13.3209 2.7904 24.2954
ESS-1 GDSC2 6.6714 10.4207 4.7783 11.683
RL95-2 GDSC2 6.8366 12.3048 3.9724 15.944
MFE-319 GDSC2 6.9253 12.643 3.8755 16.2222
KLE GDSC2 6.9803 17.3836 1.5518 26.1663
MFE-296 GDSC2 7.1055 10.78 4.9468 9.4428
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-704 GDSC2 5.3117 12.1773 2.7013 27.2064
RCC10RGB GDSC2 5.4902 10.2501 3.8077 21.2493
CAL-54 GDSC2 5.8935 12.0783 3.2785 22.5448
ACHN GDSC2 6.0668 9.8507 4.5374 15.0414
A-498 GDSC2 6.2866 10.587 4.3672 15.3434
BFTC-909 GDSC2 6.3466 9.9072 4.7583 12.7899
SW13 GDSC2 6.487 8.0157 5.8232 5.6709
KTCTL-140 GDSC2 6.6462 18.7849 0.5753 29.9681
SW156 GDSC2 6.6882 11.0916 4.4569 13.5825
TK-10 GDSC2 6.6931 9.7523 5.1305 9.4289
BB65-RCC GDSC2 6.704 8.8066 5.6122 6.3589
KTCTL-1M GDSC2 6.7386 9.5972 5.2454 8.577
LB996-RCC GDSC2 6.7933 16.0461 2.0667 24.8856
769-P GDSC2 6.879 13.7507 3.2845 19.4156
NCC021 GDSC2 6.8882 16.7367 1.7996 25.5786
SN12C GDSC2 6.93 9.6074 5.3933 7.1216
VMRC-RCW GDSC2 6.997 10.0174 5.2416 7.8959
OS-RC-2 GDSC2 7.1553 12.221 4.2692 13.3679
LB1047-RCC GDSC2 7.2601 11.0664 4.9228 9.1926
NCC010 GDSC2 7.2697 13.3608 3.7916 15.7166
VMRC-RCZ GDSC2 7.2745 10.1093 5.4045 6.1893
KTCTL-195 GDSC2 7.2889 15.1397 2.9207 19.9683
KTCTL-26A GDSC2 7.3027 12.2479 4.3702 12.3901
UO-31 GDSC2 7.3445 11.6335 4.7061 10.2935
KMRC-20 GDSC2 7.3455 13.2112 3.925 14.7911
HA7-RCC GDSC2 7.6546 12.8609 4.3322 11.7167
LB2241-RCC GDSC2 7.6974 10.3057 5.5988 4.1062
RXF 393L GDSC2 7.7537 12.1158 4.7686 8.9337
KTCTL-13 GDSC2 7.9509 12.4442 4.7475 8.6143
786-O GDSC2 8.1665 17.3091 2.5209 19.4378
KTCTL-21 GDSC2 8.6614 15.1935 3.9112 11.7159
Caki-1 GDSC2 9.8175 19.7061 2.5309 15.7579
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCT 116 GDSC2 4.9481 11.1216 2.8718 27.8691
KM12 GDSC2 6.0083 8.7412 5.0278 12.2362
COLO205 GDSC2 6.0707 9.9693 4.4823 15.3597
SW626 GDSC2 6.1487 9.9843 4.545 14.7253
CCK-81 GDSC2 6.3677 12.3057 3.5797 19.477
COLO 320HSR GDSC2 6.42 9.5044 5.023 10.9191
CL-11 GDSC2 6.435 10.4795 4.5493 13.7893
LoVo GDSC2 6.451 10.318 4.6437 13.1675
MDST8 GDSC2 6.4945 10.6495 4.5153 13.8119
HCT 15 GDSC2 6.4983 9.6159 5.0349 10.604
CW-2 GDSC2 6.5914 10.3377 4.753 12.0742
NCI-H747 GDSC2 6.6135 12.0813 3.8998 17.0057
SNU-C1 GDSC2 6.6241 9.5781 5.1603 9.4425
CaR-1 GDSC2 6.6286 8.6612 5.6225 6.5111
LS123 GDSC2 6.6656 9.7254 5.1212 9.5665
HT-29 GDSC2 6.6874 9.4446 5.2796 8.5078
LS513 GDSC2 6.6904 10.0623 4.9732 10.4205
SNU-407 GDSC2 6.6919 15.6891 2.1612 24.8255
SNU-175 GDSC2 6.7012 9.5505 5.2381 8.7297
HT-55 GDSC2 6.7179 11.1519 4.4513 13.529
C2BBe1 GDSC2 6.7655 9.2081 5.4616 7.1376
LS411N GDSC2 6.7774 9.0277 5.5613 6.475
GP5d GDSC2 6.8023 9.1344 5.5281 6.6165
NCI-H716 GDSC2 6.8306 8.5208 5.8561 4.4707
HCC2998 GDSC2 6.8332 9.114 5.5628 6.3134
SW837 GDSC2 6.855 11.0564 4.611 12.1764
SNU-C5 GDSC2 6.906 10.0508 5.1536 8.6891
DiFi GDSC2 6.9508 14.3949 3.021 20.4597
SK-CO-1 GDSC2 6.9735 9.6738 5.3941 7.0017
COLO 678 GDSC2 6.9749 9.2388 5.6109 5.638
SW48 GDSC2 6.9849 11.1088 4.6889 11.3439
LS1034 GDSC2 7.038 8.7005 5.9226 3.5401
SNU-1040 GDSC2 7.076 9.7772 5.4212 6.5696
RKO GDSC2 7.0985 13.8132 3.4307 18.063
SW948 GDSC2 7.0989 10.516 5.0727 8.6817
HT115 GDSC2 7.1719 13.6168 3.5871 17.0607
SNU-C2B GDSC2 7.2008 12.0352 4.3971 12.5019
SW620 GDSC2 7.2366 11.0984 4.8892 9.4577
SW1116 GDSC2 7.2556 11.5136 4.6981 10.5691
SW1463 GDSC2 7.4524 18.074 1.5879 24.7765
SNU-283 GDSC2 7.455 12.6036 4.31 12.3439
RCM-1 [Human ESC] GDSC2 7.4997 11.405 4.9334 8.5401
SNU-81 GDSC2 7.6343 11.0572 5.1982 6.6293
SNU-61 GDSC2 7.6707 10.7705 5.3608 5.5725
SW1417 GDSC2 7.6968 14.4263 3.5915 15.6418
T84 GDSC2 8.0185 10.6463 5.639 3.3024
NCI-H508 GDSC2 8.1935 18.3693 2.0172 21.3706
LS180 GDSC2 8.599 17.087 2.9485 16.5563
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 6.1871 9.5955 4.772 13.2161
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-7 GDSC2 5.4414 10.9433 3.425 23.4206
HLE GDSC2 5.7798 9.2776 4.5521 15.9376
SNU-398 GDSC2 5.8885 9.2594 4.6634 14.8853
HuH-1 GDSC2 6.1936 9.2804 4.9338 12.1951
SNU-449 GDSC2 6.2874 9.5222 4.8978 12.1156
Hep 3B2.1-7 GDSC2 6.4208 8.1955 5.6751 6.8142
JHH-2 GDSC2 6.5807 9.3216 5.252 8.9929
SNU-387 GDSC2 6.8585 9.9855 5.1484 8.8513
JHH-4 GDSC2 6.9171 14.1531 3.1144 20.1213
Hep-G2/C3A GDSC2 7.0702 10.0368 5.2883 7.414
JHH-6 GDSC2 7.1928 15.2684 2.7801 20.8607
JHH-1 GDSC2 7.4377 16.3456 2.4377 21.6441
SK-HEP-1 GDSC2 7.5093 11.1266 5.0764 7.6504
Huh-7 GDSC2 7.6375 9.8406 5.7781 3.1764
SNU-423 GDSC2 8.4279 25.4743 -1.3291 30.049
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 166 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2122 GDSC2 5.2116 8.9504 4.1539 20.3787
NCI-H82 GDSC2 5.3814 9.2848 4.1655 19.6617
NCI-H1355 GDSC2 5.4667 15.8273 1.0377 32.25
SBC-3 GDSC2 5.6284 8.1868 4.9208 14.2663
NCI-H1155 GDSC2 5.6661 7.7123 5.172 12.6157
NCI-H1048 GDSC2 5.7435 11.6863 3.3379 22.7703
NCI-H2081 GDSC2 5.9652 10.6627 4.0442 18.2679
CPC-N GDSC2 5.9843 9.265 4.7499 14.0284
LK-2 GDSC2 5.9907 13.0876 2.8627 24.1443
NCI-H647 GDSC2 6.1322 11.8852 3.5855 20.2035
NCI-H23 GDSC2 6.1521 9.1458 4.9627 12.153
NCI-H292 GDSC2 6.2119 11.2035 3.9948 17.7315
NCI-H2110 GDSC2 6.2763 10.9443 4.1801 16.47
EMC-BAC-2 GDSC2 6.2886 10.879 4.2234 16.1802
DMS 79 GDSC2 6.2887 10.4966 4.414 15.0589
NCI-H838 GDSC2 6.2994 9.8365 4.7522 12.9767
NCI-H526 GDSC2 6.313 15.1831 2.0955 26.2107
NCI-H211 GDSC2 6.3406 9.2514 5.0795 10.8142
SW1271 GDSC2 6.3503 9.5852 4.9219 11.7667
A-427 GDSC2 6.3579 10.475 4.4851 14.4157
NCI-H1693 GDSC2 6.3709 14.5596 2.4563 24.64
NCI-H2171 GDSC2 6.4065 8.4614 5.5304 7.771
Lu-65 GDSC2 6.4114 10.815 4.3615 14.9852
NCI-H1876 GDSC2 6.4369 13.6424 2.9706 22.2282
Calu-3 GDSC2 6.4383 8.5926 5.4933 7.9049
Lu-99A GDSC2 6.4525 10.445 4.5816 13.5404
NCI-H522 GDSC2 6.4532 11.7266 3.9419 17.2632
IST-SL2 GDSC2 6.4572 13.507 3.0556 21.7743
HCC44 GDSC2 6.4728 10.1443 4.7491 12.4555
Ms-1 GDSC2 6.4823 8.1787 5.738 6.2229
NCI-H1651 GDSC2 6.4969 12.902 3.3915 20.0322
HCC78 GDSC2 6.5033 15.3915 2.1524 25.4192
HOP-92 GDSC2 6.5079 10.9449 4.379 14.5844
NCI-H2227 GDSC2 6.5261 16.8685 1.433 27.8381
NCI-H2461 GDSC2 6.5375 9.4233 5.1646 9.6728
EKVX GDSC2 6.5421 10.8058 4.4775 13.8942
NCI-H810 GDSC2 6.5659 10.8395 4.4807 13.8037
NCI-H2023 GDSC2 6.5668 8.8103 5.4957 7.4958
NCI-H1792 GDSC2 6.5813 9.6383 5.0941 9.9842
BEN GDSC2 6.5976 12.6497 3.6023 18.6478
NCI-H720 GDSC2 6.5992 12.2461 3.8054 17.5641
COR-L105 GDSC2 6.6005 13.1837 3.3377 19.9822
COR-L23 GDSC2 6.6065 10.7148 4.5772 13.1011
NCI-H1437 GDSC2 6.6237 12.3032 3.7973 17.5338
Calu-6 GDSC2 6.6461 11.1681 4.3836 14.1416
NCI-H1944 GDSC2 6.6471 11.2519 4.3425 14.3816
DMS 53 GDSC2 6.6487 8.3735 5.7831 5.4355
NCI-H1694 GDSC2 6.6539 10.7567 4.5958 12.8482
EPLC-272H GDSC2 6.6689 20.1606 -0.0937 31.5298
COR-L311 GDSC2 6.6767 8.2892 5.8484 4.9415
NCI-H1915 GDSC2 6.6891 15.4498 2.2786 24.383
DMS 114 GDSC2 6.7007 8.6941 5.6657 6.0294
NCI-H596 GDSC2 6.7017 8.2811 5.8729 4.7156
HCC15 GDSC2 6.7263 9.6899 5.1889 8.9671
LCLC-103H GDSC2 6.7428 13.1315 3.4821 18.831
DMS 273 GDSC2 6.7482 8.5642 5.7692 5.2418
NCI-H2196 GDSC2 6.7511 10.2081 4.9503 10.3889
Lu-139 GDSC2 6.7516 13.1242 3.493 18.7491
NCI-H1650 GDSC2 6.7641 16.9923 1.5695 26.713
SW1573 GDSC2 6.7798 10.5191 4.8183 11.1244
NCI-H841 GDSC2 6.7962 10.1261 5.028 9.7771
NCI-H1975 GDSC2 6.801 9.4896 5.3498 7.7448
NCI-H1993 GDSC2 6.8111 11.0124 4.5973 12.3839
LOU-NH91 GDSC2 6.826 12.0062 4.1129 15.1854
SBC-1 GDSC2 6.8377 12.1362 4.0576 15.4644
NCI-H2373 GDSC2 6.8398 11.3907 4.4317 13.2936
NCI-H345 GDSC2 6.8539 8.4349 5.9168 4.028
LC-1/sq GDSC2 6.8566 9.3359 5.4707 6.8304
NCI-H2085 GDSC2 6.8682 10.6688 4.8152 10.8945
NCI-H2595 GDSC2 6.8725 9.688 5.3079 7.8126
NCI-H446 GDSC2 6.8748 11.56 4.3755 13.5261
CAL-12T GDSC2 6.8904 10.5915 4.8715 10.4857
KNS-62 GDSC2 6.8924 11.0391 4.6498 11.8366
HOP-62 GDSC2 6.9055 8.9355 5.7081 5.2058
NCI-H2869 GDSC2 6.9193 10.0897 5.1448 8.7083
NCI-H3255 GDSC2 6.9225 9.2912 5.5446 6.1901
NCI-H2591 GDSC2 6.927 13.7298 3.334 19.0331
NCI-H1963 GDSC2 6.9274 9.2862 5.5509 6.1373
NCI-H322M GDSC2 6.9277 12.0699 4.1636 14.6054
NCI-H524 GDSC2 6.9319 9.2512 5.5718 5.9943
COR-L321 GDSC2 6.9542 10.4971 4.9694 9.7057
LXF 289 GDSC2 6.9568 9.1301 5.651 5.4329
SBC-5 GDSC2 6.964 13.6621 3.3978 18.6099
SK-MES-1 GDSC2 6.97 9.4019 5.5263 6.1812
NCI-H1623 GDSC2 6.98 11.1971 4.6409 11.6478
NCI-H513 GDSC2 6.9804 10.8253 4.8266 10.5156
NCI-H3122 GDSC2 6.9971 11.5023 4.5024 12.4323
Lu-165 GDSC2 7.0038 10.1864 5.1629 8.3693
NCI-H2405 GDSC2 7.0113 16.941 1.7982 25.2385
COLO 668 GDSC2 7.0257 9.6522 5.4448 6.5493
NCI-H2228 GDSC2 7.0388 11.6931 4.4404 12.6855
PC-14 GDSC2 7.0658 10.7447 4.9336 9.6286
RERF-LC-MS GDSC2 7.0725 9.0523 5.7755 4.3702
NCI-H727 GDSC2 7.0772 12.7054 3.9662 15.2953
A-549 GDSC2 7.095 10.4702 5.0924 8.5693
HCC827 GDSC2 7.1001 10.7808 4.9422 9.4851
NCI-H661 GDSC2 7.1019 9.1275 5.76 4.3964
LCLC-97TM1 GDSC2 7.131 12.3259 4.1979 13.8436
HCC33 GDSC2 7.137 13.5063 3.6145 17.0158
UMC-11 GDSC2 7.1398 16.5565 2.0945 23.8031
NCI-H1755 GDSC2 7.1407 11.5773 4.5779 11.5918
RERF-LC-Sq1 GDSC2 7.1438 11.0313 4.8516 9.9268
NCI-H2029 GDSC2 7.1639 11.7199 4.5251 11.8449
EBC-1 GDSC2 7.1667 15.3109 2.7379 21.1179
NCI-H2795 GDSC2 7.1723 19.7949 0.5033 28.7653
NCI-H1781 GDSC2 7.1823 12.7189 4.0426 14.5811
NCI-H2803 GDSC2 7.1825 9.3929 5.6883 4.6521
VMRC-LCD GDSC2 7.2169 17.5666 1.6524 25.1817
NCI-H1734 GDSC2 7.2174 10.2606 5.2884 7.0451
HCC366 GDSC2 7.2244 10.8055 5.0248 8.6565
NCI-H358 GDSC2 7.2252 12.2033 4.3325 12.814
NCI-H510A GDSC2 7.2534 11.7773 4.5657 11.3673
NCI-H196 GDSC2 7.2581 11.0741 4.9175 9.23
NCI-H1563 GDSC2 7.2631 9.0674 5.9012 3.1771
LC-2/ad GDSC2 7.2692 11.0521 4.9367 9.0849
SHP-77 GDSC2 7.2713 12.2593 4.3403 12.6461
Lu-135 GDSC2 7.3002 9.9827 5.4847 5.6345
NCI-H2135 GDSC2 7.3131 10.2789 5.3494 6.4378
IA-LM GDSC2 7.3268 9.6622 5.659 4.5074
NCI-H1836 GDSC2 7.3298 12.2611 4.3844 12.2365
NCI-H1436 GDSC2 7.3487 12.2296 4.4145 12.0117
NCI-H146 GDSC2 7.3541 10.7356 5.1555 7.5336
COR-L32 GDSC2 7.3544 10.7376 5.1547 7.538
NCI-H2731 GDSC2 7.3653 10.5945 5.2328 7.0324
NCI-H1092 GDSC2 7.3796 11.0912 4.9996 8.4271
RERF-LC-KJ GDSC2 7.3894 20.993 0.0807 29.2963
ABC-1 GDSC2 7.3953 14.4686 3.3387 17.7039
NCI-H2291 GDSC2 7.4013 11.1924 4.9658 8.5803
NCI-H748 GDSC2 7.4234 9.5339 5.7854 3.5423
NCI-H250 GDSC2 7.4315 10.0045 5.566 4.8444
NCI-H2444 GDSC2 7.4498 9.3079 5.9086 2.7672
NCI-H2170 GDSC2 7.4535 10.9415 5.1267 7.4742
NCI-H1105 GDSC2 7.4562 11.916 4.6504 10.3469
NCI-H1793 GDSC2 7.4667 12.526 4.3572 12.0424
EMC-BAC-1 GDSC2 7.4855 11.8166 4.721 9.8533
NCI-H1435 GDSC2 7.4999 13.1317 4.0828 13.5159
LB647-SCLC GDSC2 7.5074 9.8509 5.6903 3.9394
NCI-H2818 GDSC2 7.5591 12.7836 4.2994 12.1417
NCI-H2810 GDSC2 7.567 11.3062 5.0301 7.7973
NCI-H2030 GDSC2 7.5731 16.1647 2.6339 20.4647
Lu-134-A GDSC2 7.5737 14.4163 3.5028 16.4119
SK-LU-1 GDSC2 7.5982 15.5893 2.9394 19.0533
NCI-H2087 GDSC2 7.6057 11.0759 5.1693 6.8673
ChaGo-K-1 GDSC2 7.6102 10.7389 5.335 5.8565
NCI-H650 GDSC2 7.6153 11.8909 4.7792 9.1929
NCI-H1568 GDSC2 7.6431 13.0961 4.2079 12.4515
COR-L303 GDSC2 7.6584 10.384 5.5367 4.5492
NCI-H1581 GDSC2 7.6663 12.711 4.4145 11.2148
NCI-H2141 GDSC2 7.6917 16.1237 2.7464 19.6693
NCI-H1869 GDSC2 7.7104 12.7677 4.4189 11.0825
IST-SL1 GDSC2 7.7117 12.2695 4.6637 9.6513
NCI-H2722 GDSC2 7.7223 13.0089 4.3093 11.6819
NCI-H1770 GDSC2 7.7752 12.7516 4.4738 10.6103
NCI-H2172 GDSC2 7.7792 11.1506 5.252 5.9961
NCI-H2369 GDSC2 7.8364 15.0523 3.3874 16.3158
NCI-H441 GDSC2 7.8372 16.8046 2.5205 20.2594
NCI-H1299 GDSC2 7.8398 16.1496 2.8471 18.8443
NCI-H226 GDSC2 7.8464 19.4129 1.2318 24.946
HARA [Human squamous cell lung carcinoma] GDSC2 7.8945 16.5668 2.6822 19.4284
NCI-H1666 GDSC2 7.9873 17.2897 2.3949 20.3986
NCI-H740 GDSC2 8.095 11.8645 5.1212 6.126
NCI-H520 GDSC2 8.1156 16.1696 3.045 17.259
NCI-H290 GDSC2 8.1506 10.0719 5.963 1.4415
NCI-H460 GDSC2 8.1585 15.8045 3.2564 16.1596
NCI-H2804 GDSC2 8.2354 17.1192 2.6662 18.6554
NCI-H209 GDSC2 8.5099 27.4512 -2.2485 31.5606
⏷ Show the Full List of 166 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 5.1708 11.0455 3.1207 25.897
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-140 GDSC2 5.4734 10.2211 3.8059 21.3209
TE-4 GDSC2 6.3472 11.7777 3.8257 18.2331
KYSE-270 GDSC2 6.5161 10.5905 4.5631 13.4581
OE33 GDSC2 6.6251 10.4221 4.7391 12.06
COLO 680N GDSC2 6.7462 10.5086 4.796 11.3574
EC-GI-10 GDSC2 6.7503 8.7568 5.6747 5.8333
TE-15 GDSC2 6.7591 9.9465 5.0876 9.5095
OE21 GDSC2 6.8866 10.6318 4.8484 10.6384
KYSE-70 GDSC2 6.9995 13.8154 3.35 18.7458
OE19 GDSC2 7.0981 13.6581 3.5077 17.6742
TE-6 GDSC2 7.1317 12.9539 3.8856 15.5865
TE-11 GDSC2 7.1363 10.7488 4.9859 9.1213
KYSE-180 GDSC2 7.2177 10.5138 5.1638 7.8155
TE-1 GDSC2 7.2201 10.4191 5.2123 7.5096
KYSE-520 GDSC2 7.5564 12.1729 4.5981 10.4107
TE-9 GDSC2 7.6196 10.1474 5.6232 4.1141
TE-8 GDSC2 7.6633 14.3925 3.5828 15.7721
KYSE-510 GDSC2 7.7928 12.5097 4.6046 9.8085
KYSE-410 GDSC2 7.8254 14.8538 3.4771 15.8965
TE-5 GDSC2 8.0826 14.6234 3.7803 13.7102
TE-10 GDSC2 8.689 10.6204 5.9927 0.8215
KYSE-450 GDSC2 9.0756 16.7914 3.4257 13.2785
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OV56 GDSC2 5.6935 7.1693 5.4275 11.0025
JHOS-4 GDSC2 6.0058 9.1117 4.8449 13.3724
OVCAR-4 GDSC2 6.4191 14.5356 2.5091 24.2767
IGROV-1 GDSC2 6.4637 12.728 3.4503 19.8396
Caov-3 GDSC2 6.7093 11.7991 4.1206 15.4825
OV-90 GDSC2 6.8032 12.261 3.9669 16.0717
DOV13 GDSC2 6.8142 11.9173 4.1477 15.0208
OVK18 GDSC2 6.8674 12.8907 3.7048 17.308
ES-2 GDSC2 6.8899 11.557 4.3893 13.402
TYK-nu GDSC2 7.0112 14.5832 2.9761 20.4933
SK-OV-3 GDSC2 7.0197 14.5116 3.0187 20.2731
TOV-21G GDSC2 7.0369 12.1559 4.2082 14.0435
A2780 GDSC2 7.1432 11.7703 4.484 12.1443
TOV-112D GDSC2 7.2055 13.4694 3.6871 16.4466
OVCAR-3 GDSC2 7.4998 16.076 2.6208 20.7149
Kuramochi GDSC2 7.602 13.7709 3.8439 14.5597
EFO-21 GDSC2 7.7443 12.4623 4.593 9.9899
OAW42 GDSC2 7.9295 17.3776 2.3072 20.8968
OVCAR-5 GDSC2 7.9371 14.9618 3.5073 15.4667
OAW28 GDSC2 8.0291 11.5906 5.2077 5.7513
EFO-27 GDSC2 8.2018 14.227 4.0591 11.9443
JHOS-2 GDSC2 8.2378 14.9612 3.7271 13.6223
OVCAR-8 GDSC2 8.3807 15.6324 3.502 14.4335
OVISE GDSC2 9.0384 18.0079 2.8126 16.1801
OVTOKO GDSC2 9.3251 24.6384 -0.2284 25.755
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BxPC-3 GDSC2 5.4715 12.7191 2.5814 27.12
KP-2 GDSC2 6.1775 10.6486 4.2407 16.4369
Panc 10.05 GDSC2 6.4585 8.824 5.3957 8.4573
MIA PaCa-2 GDSC2 6.7099 10.7828 4.6292 12.4825
HuP-T3 GDSC2 6.7347 8.4218 5.8294 4.8986
YAPC GDSC2 6.7363 12.0466 4.0191 15.9767
Capan-2 GDSC2 6.7948 11.9216 4.1297 15.18
PaTu 8988t GDSC2 6.8115 17.8535 1.1781 27.8177
SU.86.86 GDSC2 6.8711 13.2615 3.5224 18.2481
Capan-1 GDSC2 6.9885 12.4427 4.0264 15.2087
KP-4 GDSC2 7.0636 14.4976 3.0611 19.9516
KP-1N GDSC2 7.0676 11.6475 4.4858 12.3381
HPAC GDSC2 7.097 16.2293 2.2233 23.4291
SUIT-2 GDSC2 7.1055 20.1933 0.2499 29.5877
DAN-G GDSC2 7.1266 12.2911 4.2117 13.7765
Panc 08.13 GDSC2 7.3675 12.8181 4.1371 13.5555
KP-3 GDSC2 7.4214 13.5778 3.8017 15.2565
AsPC-1 GDSC2 7.4812 10.6491 5.2889 6.421
PSN1 GDSC2 7.5995 12.5592 4.4399 11.2312
MZ-PC-1 GDSC2 7.6116 10.3389 5.5272 4.6999
QGP-1 GDSC2 7.6424 13.5752 3.9711 13.769
HuP-T4 GDSC2 7.7952 15.0914 3.337 16.6673
CFPAC-1 GDSC2 7.8057 17.0633 2.3679 20.9663
Panc 02.03 GDSC2 7.9394 16.9188 2.5421 19.911
PL4 GDSC2 7.9776 19.1119 1.4835 23.7998
PaTu 8902 GDSC2 8.0916 15.5156 3.3491 15.8728
HPAF-II GDSC2 8.6705 16.5519 3.2604 14.9494
⏷ Show the Full List of 27 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IST-Mes1 GDSC2 5.7012 18.7179 -0.1957 34.3981
MPP 89 GDSC2 6.7092 11.0219 4.5091 13.2088
MSTO-211H GDSC2 6.8057 9.5471 5.3248 7.8888
NCI-H28 GDSC2 7.2576 11.8002 4.5576 11.4051
NCI-H2052 GDSC2 8.2058 14.7571 3.8038 13.2974
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PC-3 GDSC2 6.3792 13.9787 2.7537 23.3711
LNCaP clone FGC GDSC2 6.4712 12.0816 3.7798 18.0941
DU145 GDSC2 6.7672 9.8621 5.1363 9.1816
VCaP GDSC2 6.7931 10.5764 4.8005 11.1958
NCI-H660 GDSC2 7.3211 11.3322 4.8374 9.5596
22Rv1 GDSC2 7.4521 11.046 5.0747 7.795
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 8.4729 15.6124 3.5774 13.8455
Cancer Drug Sensitivity Data Curated from 53 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-MEL-3 GDSC2 5.5206 14.6952 1.6476 30.2973
COLO 792 GDSC2 5.5469 23.3395 -2.6348 38.5681
IGR-37 GDSC2 6.0957 9.2839 4.8431 13.0797
MZ-MEL-2 GDSC2 6.0972 9.993 4.4944 15.1989
SK-MEL-28 GDSC2 6.1647 16.4129 1.3545 29.1537
LOX-IMVI GDSC2 6.3097 13.9188 2.7243 23.7156
A-388 GDSC2 6.403 13.1026 3.2116 21.2061
SK-MEL-31 GDSC2 6.575 9.991 4.9125 11.1368
HT-144 GDSC2 6.6453 10.2381 4.8479 11.33
A101D GDSC2 6.6548 11.6154 4.1672 15.3774
A-375 GDSC2 6.6599 10.4875 4.7354 11.9802
RPMI-7951 GDSC2 6.6702 9.5706 5.2024 9.0438
Hs 940.T GDSC2 6.684 9.8491 5.0746 9.8058
VMRC-MELG GDSC2 6.7329 11.2713 4.4039 13.7666
CHL-1 GDSC2 6.7343 14.8332 2.6243 22.8466
MZ-MEL-7 GDSC2 6.7434 10.7694 4.6635 12.1768
HMV-II GDSC2 6.7776 9.9507 5.1006 9.3759
CP50-MEL-B GDSC2 6.7957 11.4586 4.3618 13.8327
UACC-257 GDSC2 6.8518 11.9275 4.1733 14.7663
SH-4 GDSC2 6.8755 10.7454 4.7828 11.0731
A2058 GDSC2 6.9813 11.387 4.5473 12.2079
COLO 679 GDSC2 6.9982 9.2827 5.6068 5.6044
DJM-1 GDSC2 7.0023 9.9039 5.302 7.5038
SK-MEL-24 GDSC2 7.0136 15.3979 2.5711 22.2611
G-mel GDSC2 7.0293 9.9825 5.2839 7.547
Mel Ho GDSC2 7.0749 11.3874 4.621 11.5095
IGR-1 GDSC2 7.0787 9.6073 5.5071 6.0264
A-431 GDSC2 7.1259 13.6321 3.5429 17.4164
GAK GDSC2 7.1529 10.3548 5.1936 7.7933
Hs 938.T GDSC2 7.1713 11.8542 4.4642 12.1863
G-361 GDSC2 7.2667 24.57 -1.8056 33.4076
LB2518-MEL GDSC2 7.2925 11.4525 4.7564 10.1227
WM1552C GDSC2 7.3115 10.6009 5.1904 7.4215
CP66-MEL GDSC2 7.3731 10.1926 5.4344 5.7768
IPC-298 GDSC2 7.3786 10.7503 5.1661 7.4102
WM278 GDSC2 7.403 13.6684 3.7424 15.6203
M14 GDSC2 7.4045 14.1707 3.494 16.904
Mel JuSo GDSC2 7.4112 9.7489 5.6749 4.2295
COLO 783 GDSC2 7.4209 12.3068 4.431 11.7299
LB373-MEL-D GDSC2 7.4284 10.8704 5.1434 7.431
451Lu GDSC2 7.5057 11.7541 4.7665 9.5315
SK-MEL-5 GDSC2 7.5674 10.675 5.3364 5.9406
WM115 GDSC2 7.6823 9.9356 5.7618 3.1891
WM793 GDSC2 7.7608 13.9185 3.8902 13.9102
SK-MEL-2 GDSC2 7.8038 10.5767 5.5396 4.2491
UACC-62 GDSC2 7.9317 13.0022 4.4635 10.3042
RVH-421 GDSC2 7.9458 11.8685 5.0207 7.0186
WT2-iPS GDSC2 8.1313 13.8742 4.1808 11.4389
MMAc-SF GDSC2 8.1554 13.5981 4.3316 10.545
COLO 800 GDSC2 8.339 13.3165 4.5926 8.6754
COLO 829 GDSC2 8.8197 18.0869 2.6188 17.4976
SK-MEL-30 GDSC2 10.3441 22.422 1.585 18.3256
EquiPSC Line K2 GDSC2 7.558 13.1066 4.1391 13.0525
⏷ Show the Full List of 53 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 6.7339 11.0284 4.5262 13.0343
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-402 GDSC2 5.8292 10.2641 4.1169 18.3203
Rh30 GDSC2 6.0064 12.7836 3.0278 23.349
KYM-1 GDSC2 6.3703 11.4045 4.0319 17.018
G-401 GDSC2 6.4303 9.717 4.9259 11.4924
Rh41 GDSC2 6.4419 10.3937 4.5981 13.4727
TE 441.T GDSC2 6.5813 9.4892 5.1687 9.5159
HT-1080 GDSC2 6.6079 8.0237 5.9238 4.665
RD GDSC2 6.6177 12.0378 3.9251 16.8534
EW-8 GDSC2 6.6851 10.9064 4.5469 13.0522
SK-UT-1 GDSC2 6.7024 8.3535 5.8373 4.9386
GCT GDSC2 6.921 10.1786 5.1018 8.9719
SW982 GDSC2 6.965 11.3634 4.5461 12.2598
A-204 GDSC2 7.0137 12.2985 4.1185 14.6197
SW684 GDSC2 7.1464 13.788 3.4814 17.6729
MES-SA GDSC2 7.1816 18.5361 1.1397 26.9325
SW872 GDSC2 7.3156 15.5948 2.7151 20.8062
STS-0421 GDSC2 7.5141 10.6193 5.3263 6.1191
RKN GDSC2 7.7072 12.4727 4.5611 10.2641
SK-LMS-1 GDSC2 7.7373 19.3943 1.1554 25.4569
VA-ES-BJ GDSC2 8.1126 17.0621 2.6024 19.2266
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ECC12 GDSC2 5.6302 9.8344 4.1413 18.8834
TGBC11TKB GDSC2 5.9732 15.3186 1.7357 28.5339
IM95 GDSC2 6.1012 12.9255 3.04 22.9805
KATO III GDSC2 6.1477 12.0421 3.5209 20.4868
RF-48 GDSC2 6.2001 12.8206 3.1783 22.0107
SNU-1 GDSC2 6.2096 14.1445 2.5258 24.8637
ECC10 GDSC2 6.2938 10.4089 4.4622 14.7555
MKN28 GDSC2 6.4286 10.1003 4.7332 12.6891
NUGC-3 GDSC2 6.4438 10.6335 4.4799 14.18
AGS GDSC2 6.6073 11.3088 4.2809 14.8613
23132/87 GDSC2 6.6295 10.6973 4.6051 12.8642
MKN45 GDSC2 6.631 10.1994 4.8554 11.3256
SNU-5 GDSC2 6.6916 8.5722 5.7192 5.7166
HGC-27 GDSC2 6.7705 10.8055 4.6676 12.0735
SK-GT-2 GDSC2 6.8892 9.3168 5.5059 6.5211
MKN1 GDSC2 7.1136 10.5972 5.0437 8.823
SCH GDSC2 7.1234 8.5914 6.0349 2.664
GCIY GDSC2 7.2127 11.0325 4.9037 9.4297
OCUM-1 GDSC2 7.225 14.146 3.3654 18.0366
NCI-N87 GDSC2 7.3791 13.1661 3.9734 14.4368
NUGC-4 GDSC2 7.5397 9.9288 5.6745 3.9686
MKN7 GDSC2 8.0231 11.9874 5.0157 6.8871
TMK-1 GDSC2 8.0324 15.0761 3.5215 15.1613
Hs 746.T GDSC2 8.6757 19.6543 1.7446 21.2398
RERF-GC-1B GDSC2 8.9287 18.1527 2.6646 17.06
SNG-M GDSC2 8.1989 10.0983 5.9759 1.3285
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IHH-4 GDSC2 5.1824 10.2447 3.5166 23.9333
K5 GDSC2 5.3314 9.2253 4.1446 19.9703
8305C GDSC2 6.2895 10.1537 4.5855 14.0259
HTC-C3 GDSC2 6.3503 8.988 5.219 9.9092
CAL-62 GDSC2 6.5724 10.0945 4.8586 11.4791
8505C GDSC2 6.6325 12.8838 3.5144 18.996
ASH-3 GDSC2 6.9817 9.4931 5.49 6.3791
FTC-133 GDSC2 7.0068 9.7613 5.3763 7.0268
B-CPAP GDSC2 7.0662 18.5012 1.0633 27.4697
WRO GDSC2 7.3534 18.7994 1.1468 26.4603
KMH-2 GDSC2 7.4516 10.4075 5.3853 5.8997
BHT-101 GDSC2 7.5264 13.8857 3.7296 15.3631
ML-1 [Human leukemia] GDSC2 7.5935 11.0682 5.1644 6.9241
TT2609-C02 GDSC2 7.9371 17.0605 2.4702 20.2156
⏷ Show the Full List of 14 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SCC-9 GDSC2 5.257 11.0747 3.188 25.2557
DOK GDSC2 5.42 9.901 3.9094 20.9541
Ca9-22 GDSC2 5.8192 9.4788 4.4916 16.1615
HSC-3 GDSC2 5.8198 10.6672 3.9101 19.5151
HSC-4 GDSC2 5.8885 6.9298 5.7269 8.4599
PCI-04B GDSC2 6.0515 10.1115 4.3946 15.9468
OSC-19 GDSC2 6.2485 8.6756 5.2823 9.8417
BB49-HNC GDSC2 6.3099 15.1506 2.1091 26.1702
Detroit 562 GDSC2 6.3416 10.0745 4.6706 13.3436
FaDu GDSC2 6.6831 8.247 5.8748 4.7564
SAT [Human HNSCC] GDSC2 6.7374 11.0812 4.5026 13.1658
BICR 78 GDSC2 6.8004 9.5898 5.2992 8.0645
SCC-4 GDSC2 6.854 13.9874 3.1457 20.1566
JHU-022 GDSC2 6.8841 13.3373 3.4952 18.349
LB771-HNC GDSC2 6.9341 13.5474 3.4309 18.5299
CAL-33 GDSC2 6.9417 13.3271 3.5471 17.9167
BICR 22 GDSC2 6.984 8.5956 5.935 3.5909
KOSC-2 GDSC2 6.99 11.5507 4.4726 12.6291
BB30-HNC GDSC2 7.053 10.7041 4.9438 9.5991
BICR 31 GDSC2 7.0678 11.1591 4.7291 10.8754
SAS GDSC2 7.0838 11.8802 4.3827 12.9021
JHU-029 GDSC2 7.0876 10.5771 5.0337 8.9528
CAL-27 GDSC2 7.0896 14.8995 2.8813 20.7005
HO-1-N-1 GDSC2 7.1271 11.9537 4.3802 12.7991
PCI-15A GDSC2 7.1352 11.2127 4.7549 10.5394
SCC-15 GDSC2 7.1401 9.1903 5.7567 4.3279
OSC-20 GDSC2 7.2335 14.5219 3.1848 18.8918
BHY GDSC2 7.2426 10.8244 5.0292 8.5837
NCI-H3118 GDSC2 7.2796 9.4225 5.742 4.1048
SCC-25 GDSC2 7.29 11.1315 4.9131 9.1766
HSC-2 GDSC2 7.3059 11.6377 4.6749 10.5788
JHU-011 GDSC2 7.3164 12.8055 4.104 13.8766
UPCI-SCC-090 GDSC2 7.3652 10.4644 5.2963 6.6426
PCI-06A GDSC2 7.3841 9.8517 5.607 4.6982
KON GDSC2 7.7523 12.1012 4.7747 8.901
PE/CA-PJ15 GDSC2 7.9903 12.8298 4.5884 9.4518
BICR 10 GDSC2 8.948 19.7323 1.9065 20.0369
SKN-3 GDSC2 9.7351 23.4349 0.6644 22.4934
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HT-1376 GDSC2 5.0131 10.1002 3.4213 25.0718
KU-19-19 GDSC2 6.2408 14.4463 2.4018 25.2642
RT-4 GDSC2 6.5489 12.1622 3.8052 17.7182
CAL-29 GDSC2 6.6343 11.2033 4.3562 14.339
SW780 GDSC2 6.6818 8.7196 5.6374 6.2627
J82 GDSC2 6.6831 16.1398 1.9286 25.7092
BFTC-905 GDSC2 6.737 8.9888 5.548 6.6716
639V GDSC2 6.761 8.1512 5.9855 3.8403
5637 GDSC2 6.8001 11.5685 4.3105 14.1208
HT-1197 GDSC2 6.8723 11.4132 4.4467 13.1121
SW1710 GDSC2 7.1239 11.0345 4.8346 10.0829
647V GDSC2 7.3897 12.6913 4.217 13.0446
RT-112 GDSC2 7.6905 13.4317 4.0778 13.0611
T24 GDSC2 8.4063 12.5889 4.9803 6.3355
TCCSUP GDSC2 9.3087 16.5386 3.7021 11.4498
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TC-YIK GDSC2 4.2213 17.9611 -1.1418 40.3895
JEG-3 GDSC2 5.3693 7.3211 5.0233 14.6939
CAL-39 GDSC2 6.061 10.3729 4.2738 16.6266
HEY GDSC2 6.1409 15.5947 1.7427 27.9846
OVCA433 GDSC2 6.1505 12.8762 3.1075 22.5059
HT-3 GDSC2 6.3305 8.9721 5.2093 10.0334
PA-1 GDSC2 6.3349 8.4529 5.4706 8.378
DSH1 GDSC2 6.3409 8.2233 5.5894 7.6127
BPH-1 GDSC2 6.4299 9.5904 4.9887 11.1024
SiSo GDSC2 6.6102 11.6981 4.0886 15.9599
SiHa GDSC2 6.7422 7.949 6.0713 3.3491
ACC-OV7 GDSC2 6.7913 13.5271 3.3243 19.4775
DoTc2 4510 GDSC2 6.7936 13.8209 3.1794 20.1736
LB831-BLC GDSC2 6.8182 12.7291 3.7453 17.236
SW756 GDSC2 6.8227 12.1446 4.0411 15.6007
ME-180 GDSC2 6.8301 17.2917 1.4743 26.8384
OVMIU GDSC2 6.8627 10.0373 5.1259 8.9807
C-4-I GDSC2 6.883 15.7896 2.2687 23.8574
SW962 GDSC2 6.8951 9.1599 5.5885 5.9857
C-33 A GDSC2 6.9458 14.8947 2.7673 21.6152
HeLa GDSC2 6.9809 13.1182 3.6831 17.0965
PWR-1E GDSC2 7.0007 10.4086 5.0499 9.081
NEC8 GDSC2 7.051 11.2832 4.6541 11.3744
HEC-1 GDSC2 7.1013 10.4027 5.1307 8.3155
JAR GDSC2 7.1288 10.2567 5.2239 7.6661
SKN GDSC2 7.1686 10.8927 4.9393 9.3246
PEO1 GDSC2 7.2456 13.1274 3.8889 15.2563
SW954 GDSC2 7.349 10.5722 5.2319 7.0766
Ca Ski GDSC2 7.3842 12.0551 4.5278 11.2555
UWB1.289 GDSC2 7.4509 10.3687 5.4036 5.7897
JHOS-3 GDSC2 7.6126 11.2704 5.0798 7.3924
SKG-IIIa GDSC2 7.7678 15.0009 3.361 16.6193
OMC-1 [Human cervical carcinoma] GDSC2 7.9047 10.9536 5.4273 4.7116
MS751 GDSC2 7.9621 15.7737 3.1255 17.2624
OV17R GDSC2 8.1059 14.4253 3.894 13.0544
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Leflunomide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Salsalate DM13P4C Major Increased risk of hepatotoxicity by the combination of Leflunomide and Salsalate. Rheumatoid arthritis [FA20] [15]
Baricitinib DM4ONW5 Major Additive immunosuppressive effects by the combination of Leflunomide and Baricitinib. Rheumatoid arthritis [FA20] [16]
Canakinumab DM8HLO5 Major Additive immunosuppressive effects by the combination of Leflunomide and Canakinumab. Rheumatoid arthritis [FA20] [16]
Tofacitinib DMBS370 Major Additive myelosuppressive effects by the combination of Leflunomide and Tofacitinib. Rheumatoid arthritis [FA20] [16]
Rilonacept DMGLUQS Major Additive immunosuppressive effects by the combination of Leflunomide and Rilonacept. Rheumatoid arthritis [FA20] [16]
Dexamethasone DMMWZET Major Additive immunosuppressive effects by the combination of Leflunomide and Dexamethasone. Rheumatoid arthritis [FA20] [16]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Leflunomide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Leflunomide and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [17]
Nicotinamide DMUPE07 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [18]
Pioglitazone DMKJ485 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Pioglitazone. Acute diabete complication [5A2Y] [18]
Tagraxofusp DM9HQ5U Major Increased risk of hepatotoxicity by the combination of Leflunomide and Tagraxofusp. Acute myeloid leukaemia [2A60] [18]
Midostaurin DMI6E0R Major Additive myelosuppressive effects by the combination of Leflunomide and Midostaurin. Acute myeloid leukaemia [2A60] [16]
Idarubicin DMM0XGL Major Additive myelosuppressive effects by the combination of Leflunomide and Idarubicin. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMTI0ZO Major Increased risk of hepatotoxicity by the combination of Leflunomide and Gilteritinib. Acute myeloid leukaemia [2A60] [18]
Inotersen DMJ93CT Major Increased risk of hepatotoxicity by the combination of Leflunomide and Inotersen. Amyloidosis [5D00] [18]
Siltuximab DMGEATB Major Additive immunosuppressive effects by the combination of Leflunomide and Siltuximab. Anemia [3A00-3A9Z] [16]
Dronedarone DMA8FS5 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Dronedarone. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Major Increased risk of hepatotoxicity by the combination of Leflunomide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [18]
Oxymetholone DMFXUT8 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Oxymetholone. Aplastic anaemia [3A70] [18]
Posaconazole DMUL5EW Major Increased risk of hepatotoxicity by the combination of Leflunomide and Posaconazole. Aspergillosis [1F20] [18]
Budesonide DMJIBAW Major Additive immunosuppressive effects by the combination of Leflunomide and Budesonide. Asthma [CA23] [16]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Leflunomide and Roflumilast. Asthma [CA23] [19]
Dupilumab DMOAD2Y Major Additive immunosuppressive effects by the combination of Leflunomide and Dupilumab. Atopic eczema [EA80] [16]
Clarithromycin DM4M1SG Major Increased risk of hepatotoxicity by the combination of Leflunomide and Clarithromycin. Bacterial infection [1A00-1C4Z] [18]
Levofloxacin DMS60RB Major Increased risk of hepatotoxicity by the combination of Leflunomide and Levofloxacin. Bacterial infection [1A00-1C4Z] [18]
Troleandomycin DMUZNIG Major Increased risk of hepatotoxicity by the combination of Leflunomide and Troleandomycin. Bacterial infection [1A00-1C4Z] [18]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Leflunomide and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [20]
Lomustine DMMWSUL Major Increased risk of hepatotoxicity by the combination of Leflunomide and Lomustine. Brain cancer [2A00] [16]
Eribulin DM1DX4Q Major Additive immunosuppressive effects by the combination of Leflunomide and Eribulin. Breast cancer [2C60-2C6Y] [16]
Talazoparib DM1KS78 Major Additive myelosuppressive effects by the combination of Leflunomide and Talazoparib. Breast cancer [2C60-2C6Y] [16]
Ixabepilone DM2OZ3G Major Additive immunosuppressive effects by the combination of Leflunomide and Ixabepilone. Breast cancer [2C60-2C6Y] [16]
Lapatinib DM3BH1Y Major Increased risk of hepatotoxicity by the combination of Leflunomide and Lapatinib. Breast cancer [2C60-2C6Y] [18]
LY2835219 DM93VBZ Major Additive myelosuppressive effects by the combination of Leflunomide and LY2835219. Breast cancer [2C60-2C6Y] [16]
Pralatrexate DMAO80I Major Additive immunosuppressive effects by the combination of Leflunomide and Pralatrexate. Breast cancer [2C60-2C6Y] [16]
Tucatinib DMBESUA Major Increased risk of hepatotoxicity by the combination of Leflunomide and Tucatinib. Breast cancer [2C60-2C6Y] [18]
Palbociclib DMD7L94 Major Additive myelosuppressive effects by the combination of Leflunomide and Palbociclib. Breast cancer [2C60-2C6Y] [16]
Thiotepa DMIZKOP Major Additive myelosuppressive effects by the combination of Leflunomide and Thiotepa. Breast cancer [2C60-2C6Y] [16]
Cabazitaxel DMPAZHC Major Additive myelosuppressive effects by the combination of Leflunomide and Cabazitaxel. Breast cancer [2C60-2C6Y] [16]
Bosutinib DMTI8YE Major Increased risk of hepatotoxicity by the combination of Leflunomide and Bosutinib. Breast cancer [2C60-2C6Y] [16]
Trastuzumab Emtansine DMU1LXS Major Increased risk of hepatotoxicity by the combination of Leflunomide and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [18]
Fluoxymesterone DMUHCF1 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Fluoxymesterone. Breast cancer [2C60-2C6Y] [18]
Fenofibric acid DMGO2MC Major Increased risk of hepatotoxicity by the combination of Leflunomide and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [18]
Macitentan DMP79A1 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Macitentan. Cardiovascular disease [BA00-BE2Z] [18]
Chenodiol DMQ8JIK Major Increased risk of hepatotoxicity by the combination of Leflunomide and Chenodiol. Cholelithiasis [DC11] [18]
Corticotropin DMP9TWZ Major Additive immunosuppressive effects by the combination of Leflunomide and Corticotropin. Chronic kidney disease [GB61] [16]
Anisindione DM2C48U Moderate Decreased metabolism of Leflunomide caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [21]
Regorafenib DMHSY1I Major Increased risk of hepatotoxicity by the combination of Leflunomide and Regorafenib. Colorectal cancer [2B91] [18]
Intedanib DMSTA36 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Intedanib. Colorectal cancer [2B91] [18]
Aflibercept DMT3D5I Major Additive immunosuppressive effects by the combination of Leflunomide and Aflibercept. Colorectal cancer [2B91] [16]
Capecitabine DMTS85L Major Additive myelosuppressive effects by the combination of Leflunomide and Capecitabine. Colorectal cancer [2B91] [16]
Pasireotide DMHM7JS Major Increased risk of hepatotoxicity by the combination of Leflunomide and Pasireotide. Cushing syndrome [5A70] [18]
Ivacaftor DMZC1HS Major Increased risk of hepatotoxicity by the combination of Leflunomide and Ivacaftor. Cystic fibrosis [CA25] [18]
Nefazodone DM4ZS8M Major Increased risk of hepatotoxicity by the combination of Leflunomide and Nefazodone. Depression [6A70-6A7Z] [18]
Milnacipran DMBFE74 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Milnacipran. Depression [6A70-6A7Z] [18]
Polatuzumab vedotin DMF6Y0L Major Increased risk of hepatotoxicity by the combination of Leflunomide and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [16]
Lisocabtagene maraleucel DMP45ME Major Additive immunosuppressive effects by the combination of Leflunomide and Lisocabtagene maraleucel. Diffuse large B-cell lymphoma [2A81] [16]
Axicabtagene ciloleucel DMYHN59 Major Additive myelosuppressive effects by the combination of Leflunomide and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [16]
Fosphenytoin DMOX3LB Major Increased risk of hepatotoxicity by the combination of Leflunomide and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [18]
Cannabidiol DM0659E Major Increased risk of hepatotoxicity by the combination of Leflunomide and Cannabidiol. Epileptic encephalopathy [8A62] [18]
Dantrolene DM1D8XY Major Increased risk of hepatotoxicity by the combination of Leflunomide and Dantrolene. Fever [MG26] [18]
Bay 80-6946 DMLOS5R Major Additive myelosuppressive effects by the combination of Leflunomide and Bay 80-6946. Follicular lymphoma [2A80] [16]
Atovaquone DMY4UMW Major Increased risk of hepatotoxicity by the combination of Leflunomide and Atovaquone. Fungal infection [1F29-1F2F] [18]
Sunitinib DMCBJSR Major Increased risk of hepatotoxicity by the combination of Leflunomide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [18]
Avapritinib DMK2GZX Major Additive immunosuppressive effects by the combination of Leflunomide and Avapritinib. Gastrointestinal stromal tumour [2B5B] [16]
177Lu-DOTATATE DMT8GVU Major Additive immunosuppressive effects by the combination of Leflunomide and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [16]
Procarbazine DMIK367 Major Additive immunosuppressive effects by the combination of Leflunomide and Procarbazine. Hodgkin lymphoma [2B30] [16]
Brentuximab vedotin DMWLC57 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [16]
Rilpivirine DMJ0QOW Major Increased risk of hepatotoxicity by the combination of Leflunomide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [18]
Darunavir DMN3GCH Major Increased risk of hepatotoxicity by the combination of Leflunomide and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [18]
Maraviroc DMTL94F Major Increased risk of hepatotoxicity by the combination of Leflunomide and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [18]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Mipomersen. Hyper-lipoproteinaemia [5C80] [18]
Rosuvastatin DMMIQ7G Major Increased risk of hepatotoxicity by the combination of Leflunomide and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [17]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Leflunomide and BMS-201038. Hyper-lipoproteinaemia [5C80] [18]
Captopril DM458UM Major Increased risk of hepatotoxicity by the combination of Leflunomide and Captopril. Hypertension [BA00-BA04] [18]
Tolvaptan DMIWFRL Major Increased risk of hepatotoxicity by the combination of Leflunomide and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [18]
Pirfenidone DM6VZFQ Major Increased risk of hepatotoxicity by the combination of Leflunomide and Pirfenidone. Idiopathic interstitial pneumonitis [CB03] [18]
Givosiran DM5PFIJ Major Increased risk of hepatotoxicity by the combination of Leflunomide and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [18]
Febuxostat DMDEXQ0 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [18]
Lesinurad DMUR64T Moderate Decreased metabolism of Leflunomide caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [22]
Olaratumab DMNYOIX Major Additive immunosuppressive effects by the combination of Leflunomide and Olaratumab. Kaposi sarcoma [2B57] [16]
Nelarabine DMB6VEG Major Additive myelosuppressive effects by the combination of Leflunomide and Nelarabine. Leukaemia [2A60-2B33] [16]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Leflunomide and Denosumab. Low bone mass disorder [FB83] [23]
Crizotinib DM4F29C Major Increased risk of hepatotoxicity by the combination of Leflunomide and Crizotinib. Lung cancer [2C25] [18]
Brigatinib DM7W94S Major Additive immunosuppressive effects by the combination of Leflunomide and Brigatinib. Lung cancer [2C25] [16]
Ceritinib DMB920Z Major Increased risk of hepatotoxicity by the combination of Leflunomide and Ceritinib. Lung cancer [2C25] [18]
Lurbinectedin DMEFRTZ Major Additive immunosuppressive effects by the combination of Leflunomide and Lurbinectedin. Lung cancer [2C25] [16]
Alectinib DMP1I6Y Major Increased risk of hepatotoxicity by the combination of Leflunomide and Alectinib. Lung cancer [2C25] [18]
Osimertinib DMRJLAT Major Additive immunosuppressive effects by the combination of Leflunomide and Osimertinib. Lung cancer [2C25] [16]
BIBW 2992 DMTKD7Q Major Increased risk of hepatotoxicity by the combination of Leflunomide and BIBW 2992. Lung cancer [2C25] [18]
Capmatinib DMYCXKL Major Increased risk of hepatotoxicity by the combination of Leflunomide and Capmatinib. Lung cancer [2C25] [18]
Selpercatinib DMZR15V Major Increased risk of hepatotoxicity by the combination of Leflunomide and Selpercatinib. Lung cancer [2C25] [18]
Belimumab DM3OBQF Major Additive immunosuppressive effects by the combination of Leflunomide and Belimumab. Lupus erythematosus [4A40] [16]
Inotuzumab ozogamicin DMAC130 Major Additive immunosuppressive effects by the combination of Leflunomide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [16]
Calaspargase pegol DMQZBXI Major Additive immunosuppressive effects by the combination of Leflunomide and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [16]
Ofatumumab DM295PR Major Additive myelosuppressive effects by the combination of Leflunomide and Ofatumumab. Mature B-cell leukaemia [2A82] [16]
Obinutuzumab DM3BVAE Major Additive immunosuppressive effects by the combination of Leflunomide and Obinutuzumab. Mature B-cell leukaemia [2A82] [16]
Idelalisib DM602WT Major Additive myelosuppressive effects by the combination of Leflunomide and Idelalisib. Mature B-cell leukaemia [2A82] [16]
GDC-0199 DMH0QKA Major Additive myelosuppressive effects by the combination of Leflunomide and GDC-0199. Mature B-cell leukaemia [2A82] [16]
IPI-145 DMWA24P Major Additive myelosuppressive effects by the combination of Leflunomide and IPI-145. Mature B-cell leukaemia [2A82] [16]
Acalabrutinib DM7GCVW Major Additive myelosuppressive effects by the combination of Leflunomide and Acalabrutinib. Mature B-cell lymphoma [2A85] [16]
Blinatumomab DMGECIJ Major Additive immunosuppressive effects by the combination of Leflunomide and Blinatumomab. Mature B-cell lymphoma [2A85] [16]
Ibrutinib DMHZCPO Major Additive myelosuppressive effects by the combination of Leflunomide and Ibrutinib. Mature B-cell lymphoma [2A85] [16]
Tisagenlecleucel DMM9BJD Major Additive immunosuppressive effects by the combination of Leflunomide and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [16]
Ponatinib DMYGJQO Major Increased risk of hepatotoxicity by the combination of Leflunomide and Ponatinib. Mature B-cell lymphoma [2A85] [16]
Arry-162 DM1P6FR Major Increased risk of hepatotoxicity by the combination of Leflunomide and Arry-162. Melanoma [2C30] [18]
Vemurafenib DM62UG5 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Vemurafenib. Melanoma [2C30] [18]
Ipilimumab DMJTIYK Major Increased risk of hepatotoxicity by the combination of Leflunomide and Ipilimumab. Melanoma [2C30] [18]
Danazol DML8KTN Major Increased risk of hepatotoxicity by the combination of Leflunomide and Danazol. Menstrual cycle bleeding disorder [GA20] [18]
Exjade DMHPRWG Major Increased risk of hepatotoxicity by the combination of Leflunomide and Exjade. Mineral absorption/transport disorder [5C64] [18]
Carfilzomib DM48K0X Major Additive myelosuppressive effects by the combination of Leflunomide and Carfilzomib. Multiple myeloma [2A83] [16]
Panobinostat DM58WKG Major Additive immunosuppressive effects by the combination of Leflunomide and Panobinostat. Multiple myeloma [2A83] [16]
Selinexor DMBD4K3 Major Additive myelosuppressive effects by the combination of Leflunomide and Selinexor. Multiple myeloma [2A83] [16]
Belantamab mafodotin DMBT3AI Major Additive myelosuppressive effects by the combination of Leflunomide and Belantamab mafodotin. Multiple myeloma [2A83] [16]
Elotuzumab DMEYHG9 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Elotuzumab. Multiple myeloma [2A83] [16]
Daratumumab DMKCIUZ Major Additive immunosuppressive effects by the combination of Leflunomide and Daratumumab. Multiple myeloma [2A83] [16]
Tecfidera DM2OVDT Major Additive immunosuppressive effects by the combination of Leflunomide and Tecfidera. Multiple sclerosis [8A40] [16]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Leflunomide and Siponimod. Multiple sclerosis [8A40] [17]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Leflunomide and Fingolimod. Multiple sclerosis [8A40] [16]
Ocrelizumab DMEZ2KH Major Additive immunosuppressive effects by the combination of Leflunomide and Ocrelizumab. Multiple sclerosis [8A40] [16]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Leflunomide and Ozanimod. Multiple sclerosis [8A40] [19]
Romidepsin DMT5GNL Major Additive immunosuppressive effects by the combination of Leflunomide and Romidepsin. Mycosis fungoides [2B01] [16]
Decitabine DMQL8XJ Major Additive immunosuppressive effects by the combination of Leflunomide and Decitabine. Myelodysplastic syndrome [2A37] [16]
Fedratinib DM4ZBK6 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Fedratinib. Myeloproliferative neoplasm [2A20] [18]
Ruxolitinib DM7Q98D Major Additive myelosuppressive effects by the combination of Leflunomide and Ruxolitinib. Myeloproliferative neoplasm [2A20] [16]
Dasatinib DMJV2EK Major Additive myelosuppressive effects by the combination of Leflunomide and Dasatinib. Myeloproliferative neoplasm [2A20] [16]
Omacetaxine mepesuccinate DMPU2WX Major Additive immunosuppressive effects by the combination of Leflunomide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [16]
Inebilizumab DMI0RHA Major Additive immunosuppressive effects by the combination of Leflunomide and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [16]
Bupropion DM5PCS7 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Bupropion. Nicotine use disorder [6C4A] [18]
Atezolizumab DMMF8U0 Major Additive immunosuppressive effects by the combination of Leflunomide and Atezolizumab. Non-small cell lung cancer [2C25] [16]
Entrectinib DMMPTLH Major Increased risk of hepatotoxicity by the combination of Leflunomide and Entrectinib. Non-small cell lung cancer [2C25] [16]
Olaparib DM8QB1D Major Additive myelosuppressive effects by the combination of Leflunomide and Olaparib. Ovarian cancer [2C73] [16]
Rucaparib DM9PVX8 Major Additive immunosuppressive effects by the combination of Leflunomide and Rucaparib. Ovarian cancer [2C73] [16]
MK-4827 DMLYGH4 Major Additive myelosuppressive effects by the combination of Leflunomide and MK-4827. Ovarian cancer [2C73] [16]
Choline salicylate DM8P137 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Choline salicylate. Postoperative inflammation [1A00-CA43] [15]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Leflunomide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [24]
ABIRATERONE DM8V75C Major Increased risk of hepatotoxicity by the combination of Leflunomide and ABIRATERONE. Prostate cancer [2C82] [18]
Bicalutamide DMZMSPF Major Increased risk of hepatotoxicity by the combination of Leflunomide and Bicalutamide. Prostate cancer [2C82] [18]
Brodalumab DMASDQ6 Major Additive immunosuppressive effects by the combination of Leflunomide and Brodalumab. Psoriasis [EA90] [16]
Ustekinumab DMHTYK3 Major Additive immunosuppressive effects by the combination of Leflunomide and Ustekinumab. Psoriasis [EA90] [16]
Tildrakizumab DMLW9HG Major Additive immunosuppressive effects by the combination of Leflunomide and Tildrakizumab. Psoriasis [EA90] [16]
Risankizumab DMM32GT Major Additive immunosuppressive effects by the combination of Leflunomide and Risankizumab. Psoriasis [EA90] [16]
Ixekizumab DMXW92T Major Additive immunosuppressive effects by the combination of Leflunomide and Ixekizumab. Psoriasis [EA90] [16]
Ambrisentan DMD1QXW Major Increased risk of hepatotoxicity by the combination of Leflunomide and Ambrisentan. Pulmonary hypertension [BB01] [18]
Axitinib DMGVH6N Major Increased risk of hepatotoxicity by the combination of Leflunomide and Axitinib. Renal cell carcinoma [2C90] [18]
Temsirolimus DMS104F Major Additive immunosuppressive effects by the combination of Leflunomide and Temsirolimus. Renal cell carcinoma [2C90] [16]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Leflunomide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [25]
Mogamulizumab DMISH0Z Major Additive myelosuppressive effects by the combination of Leflunomide and Mogamulizumab. Sezary syndrome [2B02] [16]
Larotrectinib DM26CQR Major Increased risk of hepatotoxicity by the combination of Leflunomide and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [18]
PDX-101 DM6OC53 Major Increased risk of hepatotoxicity by the combination of Leflunomide and PDX-101. Solid tumour/cancer [2A00-2F9Z] [16]
Ifosfamide DMCT3I8 Major Additive myelosuppressive effects by the combination of Leflunomide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [16]
Docetaxel DMDI269 Major Additive immunosuppressive effects by the combination of Leflunomide and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [16]
Trabectedin DMG3Y89 Major Additive immunosuppressive effects by the combination of Leflunomide and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [16]
Mitoxantrone DMM39BF Major Additive immunosuppressive effects by the combination of Leflunomide and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [16]
LEE011 DMMX75K Major Additive immunosuppressive effects by the combination of Leflunomide and LEE011. Solid tumour/cancer [2A00-2F9Z] [16]
Taxol DMUOT9V Major Additive myelosuppressive effects by the combination of Leflunomide and Taxol. Solid tumour/cancer [2A00-2F9Z] [16]
Methyltestosterone DMWLFGO Major Increased risk of hepatotoxicity by the combination of Leflunomide and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [18]
Pomalidomide DMTGBAX Major Additive myelosuppressive effects by the combination of Leflunomide and Pomalidomide. Systemic sclerosis [4A42] [16]
Plicamycin DM7C8YV Major Additive myelosuppressive effects by the combination of Leflunomide and Plicamycin. Testicular cancer [2C80] [16]
Fostamatinib DM6AUHV Major Increased risk of hepatotoxicity by the combination of Leflunomide and Fostamatinib. Thrombocytopenia [3B64] [18]
Eltrombopag DMOGFIX Major Increased risk of hepatotoxicity by the combination of Leflunomide and Eltrombopag. Thrombocytopenia [3B64] [18]
Lenvatinib DMB1IU4 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Lenvatinib. Thyroid cancer [2D10] [18]
Trimetrexate DMDEA85 Major Additive immunosuppressive effects by the combination of Leflunomide and Trimetrexate. Toxoplasmosis [1F57] [16]
Belatacept DMXLYQF Major Additive immunosuppressive effects by the combination of Leflunomide and Belatacept. Transplant rejection [NE84] [16]
Tolbutamide DM02AWV Moderate Decreased metabolism of Leflunomide caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [16]
Durvalumab DM4PVDY Major Additive immunosuppressive effects by the combination of Leflunomide and Durvalumab. Ureteral cancer [2C92] [16]
Elagolix DMB2C0E Major Increased risk of hepatotoxicity by the combination of Leflunomide and Elagolix. Uterine fibroid [2E86] [18]
Amiodarone DMUTEX3 Major Increased risk of hepatotoxicity by the combination of Leflunomide and Amiodarone. Ventricular tachyarrhythmia [BC71] [18]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Leflunomide and Valganciclovir. Virus infection [1A24-1D9Z] [17]
⏷ Show the Full List of 161 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Leflunomide 20 mg tablet 20 mg Oral Tablet Oral
Leflunomide 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6825).
2 Leflunomide FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 077090.
4 ClinicalTrials.gov (NCT04361214) Leflunomide in Mild COVID-19 Patients. U.S. National Institutes of Health.
5 BDDCS applied to over 900 drugs
6 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
9 On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013 Apr 25;56(8):3148-67. doi: 10.1021/jm301848w.
10 Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7.
11 Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 2015 May 18;28(5):872-85.
12 Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004 Jan;36(1):82-4.
13 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
14 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
15 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
16 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
17 Cerner Multum, Inc. "Australian Product Information.".
18 Canadian Pharmacists Association.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
21 Chonlahan J, Halloran MA, Hammonds A "Leflunomide and warfarin interaction: case report and review of the literature." Pharmacotherapy 26 (2006): 868-71. [PMID: 16716139]
22 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
23 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
24 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
25 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]